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BACKGROUND: Glaucoma, the second leading cause of blindness worldwide, is a 
progressive neurodegenerative optic neuropathy. Its progression is monitored by 
documenting morphological changes to the optic nerve head, inner retinal layers, and 
quantifying the visual field over time. Visual field testing is done using table-top 
instruments that cannot be used for home self monitoring and are not practical for 
population-based screening. A tablet-based application, Melbourne Rapid Fields (MRF), 
was developed recently on the iPad platform to facilitate visual field testing outside the 
traditional clinical setting, but has not been tested in low-income nations. 
OBJECTIVE: To test usability of the MRF in a low-resource setting, to compare its 
results, and to assess the correlation and agreement with those of the Humphrey Field 
Analyzer 24-2 SITA standard (HFA), considered as clinical standard for testing visual 
field.  
METHODS: Thirty-two subjects with and those without glaucoma attending their clinical 
appointment at the UNC Kittner Eye Center (n= 13) and Tema Eye Center in Ghana (n= 
19) were recruited between June and July 2018. All participants underwent visual field 
testing with the MRF and HFA. They were then administered an Ease of Use 
Questionnaire to determine perceptions of the new MRF testing. Global (mean 
deviation, MD; pattern standard deviation, PSD), reliability indices (false positive rate, 
FPR; false negative rate, FNR; and fixation loss) and testing duration of the two 
methods were compared. The results were also assessed for correlation and 
agreement.   
RESULTS: Twenty-nine patients were included in the final analysis, 11 from UNC 
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Kittner Eye Center (age: 68 ± 8 years old, range: 49-76) and 18 from Tema Eye Center 
(age: 42 ± 12 years old, range: 18-62). Overall, 48% of participants had glaucoma and 
52% were healthy patients. MRF MD was significantly higher than HFA MD at UNC (< 
0.01); no difference in MD was observed between the two devices in Tema (p = 0.89). 
PFR and FNR were comparable between the two methods at both study sites (all p > 
0.05). MD and PSD from the two devices were strongly (r = 0.71, p < 0.001) and 
moderately (r = 0.48, p < 0.001) correlated, respectively. Agreement analysis revealed 
that MRF tended to generate significantly higher MD (bias: 1.8 ± 0.41 dB, p = 0.03) and 
PSD (bias: 1.5 dB ± 0.34 dB; p = 0.03) with wide limits of agreements. Subgroup 
analysis comparing MRF and HFA results in Ghana and UNC separately demonstrated 
similar mean MD in TEMA (p=0.89), but significantly different at UNC (p<0.01). The 
MRF was well-tolerated by patients at all sites.  
CONCLUSIONS: Although, the MRF and HFA global indices correlated strongly for MD 
and moderately for PSD, the agreement analysis indicated that MRF tended to 
underestimate MD and PSD values than HFA. In both agreement analysis, the mean 
differences were significant, suggesting a poor agreement between the two devices. 
Further studies should investigate this discrepancy and refine the MRF application to 
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As the health care system evolves to become more patient-centered and 
technology driven, focus shifts to patient outcomes and team-based approaches to 
care. With this development has come an increased interest in Technology-Enabled 
Care (TEC) or the use of technology to help patients manage their own health.1 
Delivering care outside of the traditional setting of a doctor’s office may ultimately 
become more efficient and cost-saving. This may include improved patient management 
of one’s own health through education, remote monitoring, and increased treatment 
adherence. Implementation of TEC may also improve collaboration between medical 
team members, the patient, and his family. Portable health technologies for instance 
allow for screening of prevalent diseases and management of chronic conditions.  
Like other clinical fields, ophthalmology continues to experience technological 
advances that assist the clinician in the diagnosis, treatment, and monitoring of 
diseases. With this incorporation has come the introduction of modalities that allow 
remote patient monitoring (RPM), and thus a paradigm shift of medical practice from the 
hospital setting to the field and home environment for some conditions. RPM uses 
technologies with a wide range of applications to gather health data outside of the 
traditional clinic setting to help medical decision-making.2 This type of technology is not 
new to the health care system. Indeed, RPM has been used for some time in patients 
with conditions such as diabetes to monitor glycaemia, systemic hypertension to 
monitor blood pressure and heart disease to monitor heart beat rhythm. 
Ophthalmologists have also used similar technologies to monitor the progression of 
common diseases such as age-related macular degeneration and diabetic retinopathy.3 
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Other such technologies are being introduced for use in glaucoma to monitor intraocular 
pressure, treatment compliance, or visual field. This paper specifically focuses on the 
the use of the Melbourne rapid Field (MRF), an iPad-based application developed 





BACKGROUND AND SIGNIFICANCE 
Glaucoma is a slow progressive neurodegenerative disorder of the optic nerve, 
characterized by the death of retinal ganglion cells and their axons, leading to the 
characteristic appearance of the optic nerve head and corresponding visual field 
deficits. Patients with untreated visual field loss are at increased odds of having 
difficulties with activities of daily living, social functioning, and emotional well-being.4 If 
left untreated or treated inadequately, it leads to irreversible blindness. Glaucoma is the 
second leading overall cause of blindness worldwide after cataract, but the first cause of 
irreversible blindness. It was estimated that there were 64.3 million people with 
glaucoma among those aged 40-80 years worldwide in 2013 and that this number is 
expected to reach 76 million in 2020 and 112 million in 2040.5 The prevalence of 
glaucoma varies across regions, but it is highest in Africa, particularly in West Africa 
compared to other regions of the world.5,6 Within the Unites Sates, people of African 
origin are more affected than those of European and Asian descent. In addition, among 
people with glaucoma in Africa 87.1% to 98.5% are not aware that they have glaucoma 
at the time of diagnosis versus approximately 50% in the U.S.7 This highlights the 
importance of screening for early detection to prevent the resulting visual impairment, 
particularly on people at high risk, such as those of African heritage.  
Since the disease is known to progress even after intraocular pressure has been 
lowered and maintained within normal range, treatment is aimed at slowing the 
progression. Thus, once the diagnosis has been made and the treatment initiated, the 
patient must be monitored longitudinally to determine whether progression is occurring 
or not. One common method to monitor glaucoma progression is in-office visual field 
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testing using automated perimeter with instruments such as the Humphrey Field 
Analyzer (HFA, Cal Zeiss Mediate, Dublin, California, USA). This device is inadequate 
for screening because it is heavy, not easily transportable, expensive, time-consuming, 
difficult to interpret, uncomfortable for patients, and is affected by a learning effect.  
Screening with TEC such as the MRF may not only be suitable for screening for 
glaucoma in population at risk, but also for self monitoring in the home environment.  To 
date, the MRF has not been tested in a population at risk for glaucoma, such as black 
Africans. The purpose of this study was to conduct an independent investigation 
evaluating the performance of the MRF application for use in clinic-based visual field 
testing in a low-resource setting. Research volunteers with and without glaucoma 
underwent testing with both the MRF application and HFA and the results were 
compared to determine level of agreement. The volunteers also completed an Ease of 






Patients and Enrollment Procedure 
A 5-week study comparing the MRF and the HFA was undertaken at the UNC 
Kittner Eye Center in Chapel Hill, NC and Tema Eye Center in Tema, Ghana. The UNC 
Institutional Review Board of Human Research Ethics approved the study protocol.  
Consecutive subjects attending their clinical appointment at the UNC Kittner Eye 
Center and Tema Eye Center were recruited between June and July 2018. The study 
population consisted of normal control subjects with healthy eyes and subjects with 
clinically diagnosed glaucoma. Inclusion criteria included age 18 years or older, 
willingness to perform the tablet-based visual field and HFA, and corrected visual acuity 
of 20/40 or better per eye. Patients were excluded from the study if they had a diagnosis 
of diabetic proliferative retinopathy or neurological disorders that can affect the visual 
field. Patients were also excluded if they were taking a medication that can affect the 
visual field. Thirty-two included volunteer participants meeting inclusion criteria were 
entered into the study after signing an informed consent form reviewed by the UNC 
Institutional Review Board. 
Testing Procedure 
I tested participants’ visual fields with the MRF application on the iPad and the 
HFA 24-2 SITA standard in each participant in no particular order. All participants had 
no prior experience with the iPad-based visual field application. Control participants 
were new to both the HFA and MRF. The two tests require the subject to signal (by 
pressing a button in HFA and by touching the iPad screen on the MRF application) 
whenever they see a light in their field of vision.  
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The MRF is a visual field application on that works on the iPad-tablet platform. It 
was recently developed to facilitate perimetry outside the traditional clinical setting.8 It 
has all the testing modes and outputs of the HFA, but offers more test points (it covers a 
larger field).  It is easy to use, well liked by subjects, and only takes about 3 minutes per 
eye, compared to 30-45 minutes for HFA. Recently published non-randomized clinical 
trials showed high correlation between the MRF and the HFA results.8–10 Home-based 
visual field testing using the MRF has an increased sensitivity and specificity for rapid 
visual loss progression. Even with a compliance rate of 63%, weekly MRF home 
monitoring achieved a sensitivity of 0.8 for rapid visual loss within 0.9 years of use.11  
Testing was performed in a dimly lit room to minimize glare on the iPad screen. 
The patient was seated approximately 33 cm or 13 inches from the iPad screen. The 
initial UNC cohort had difficult maintaining an adequate viewing distance. This 
observation prompted me to build a custom box to serve as an iPad platform when 
testing in the Tema, Ghana cohort (Figure 1). The iPad tablet was held upright using an 
iPad stand with keyboard. Rather than pressing the screen, the patient used the space 
key on the keyboard to record responses to presented stimulus. This inputting method 
was used to minimize the time in which the patient’s fingers would obscure the screen 
while also lowering the likelihood of leaving fingerprints, which could affect visualization 
of targets. Targets are presented for 300-ms with an interval of 700-1100 ms between 
presentations. On the iPad’s 5-cd.m-2 background, the luminous output was previously 
found to return approximately 31 dB of operating range.8 This value has been shown to 
be similar to the HFA’s weber fraction for discriminating changes in stimulus brightness. 
The weber fraction allows for the minimal amount by which the stimulus intensity must 
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be changed in order for the subject to note the difference. The stimulus size also 
changes throughout the testing, increasing with eccentricity, to account for the tangent 
effect of a planar tablet screen.8 Volunteers’ right eye was tested first with proper 
occlusion of the left eye. Testing of the left eye followed completion of the fellow eye. If 
applicable, subjects with refractive error were prompted to wear their prescribed lenses 
throughout testing. Verbal and on screen prompting was used to instruct participants on 
testing practices.  
Full testing of MRF iPad application characteristics were published by Vingrys et 
al.8 The MRF uses either a modified 24-2 grid or radial orientation centered at fixation. A 
total of 66 points are tested to determine central and peripheral visual defects compared 
to the 54 points tested by the Humphrey 24-2 SITA Standard. The iPad’s small 
dimensions (195 x150 mm) limits initial perimetry testing to an island of vision 
measuring 15° x 12° from central fixation. To test peripheral vision, the fixation point is  
moved to each of the four corners of the screen (Figure 2). Verbal instructions direct the 
subject to fixate on this new target throughout testing. This increases peripheral vision 
testing to 30° along the horizontal and 24° along the vertical. It is important to note that 
during central vision testing (15° x 12°), fixation loss is tested by a blind-spot monitor. 
The blind spot is first located at the beginning of the examination. During visual field 
testing, a 19-db stimulus is presented 8 to 10 times at the location of the blind spot. 
Fixation loss is detected when the subject presses the keyboard during this time. For 
peripheral testing, blind-spot monitoring cannot be implemented. To minimize this 
limitation, regular voice prompting instructs the subject to maintain fixation at one of the 
four corners of the screen.  
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False positive and false negative responses are tested throughout the MRF 
testing. False positive testing occurs during the time between target presentations (700-
1100 ms) when no stimulus is being presented. A false positive is recorded if the 
subject presses the keyboard or screen without a corresponding stimulus. In contrast, a 
false negative is recorded when the subject fails to respond to a presented stimulus. 
Parameters of interest for both tests were the mean deviation (MD), patter standard 
deviation (PSD), false positive rate (FPR), false negative rate (FNR), and testing 
duration.  
Following testing with the MRF and HFA, subjects completed a questionnaire 
asking about perception of their general health and about their satisfaction and ease of 
use of the iPad-based MRF testing. The questionnaire also assessed willingness to use 
the MRF at home and elicited opinions on any other positive or negative aspects of this 
type of testing. The questionnaire appears in Appendix 2.  
Statistical Analysis 
I performed statistical analysis using MATLAB software. Only data from one eye 
per patient was used in the analysis. I chose data from a randomly selected eye in the 
control patients and the eye with worse MD by HFA in glaucoma patients. I compared 
the MRF and HFA results using the Student t-test for paired or unpaired samples where 
appropriate. I assessed the correlation between the results of the MRF and HFA using 
Pearson correlation coefficient, which determine the strength of association, and linear 
regression which fits the best line through the data. I performed a Bland-Altman analysis 
to evaluate the agreement between the MRF and HFA. I also present simple frequency 
distributions from the results of the Ease of Use questionnaire. 
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RESULTS 
Demographic and Clinical Characteristics of Participants  
I recruited 31 patients from 2 clinical sites, UNC Kittner Eye Center, Chapel Hill, 
NC and Tema Eye Center, Tema, Ghana. Of those eligible, two patients were excluded 
because they could not perform the visual field testing via the MRF application. Twenty-
nine patients were included in the final analysis, including 13 from UNC Kittner Eye 
Center (age: 68 ± 8 years, range: 49-76) and 19 from Tema Eye Center (age: 42 ± 12 
years, range: 18-62). Study participants had either a diagnosis of glaucoma (diagnosed 
by local optometrist or ophthalmologist) in at least one eye or were control patients 
(normal intraocular pressure, no previous visual field deficits and normal optic nerve). 
Table 1 presents basic demographic characteristics of the glaucoma and control 
groups. The size of the two groups was similar with no statistically significant difference 
between gender (X2 p-value= 0.959) and race (X2 p-value= 0.077). Glaucoma patients 
were significantly older than controls; 61 ± 12 years versus 42 ± 15 years old 
respectively (p <0.001). The average years of education for the glaucoma and control 
groups were similar between the two groups (p= 0.786). Average MD and PSD results 
for the Glaucoma group was -8.12 ± 7.30 and -2.47 ± 2.01 respectively. Average MD 
and PSD results for the control group was 5.40 ± 74.17 and -2.21 ± 0.66 respectively. 
Glaucoma and control groups had a statistically significant difference between MD and 
PSD (p <0.05). 
Comparison Between MRF and HFA 
Figure 3 represents visual field results from 3 patients with mild (MD no worse 
than -6 dB), moderate (MD between -6 and -12 dB) and severe visual field loss (MD 
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worse than -12 dB). Table 2 presents the average MRF and HFA parameters (MD, 
PSD, FPR, FNR and testing duration) for all patients. Table 3 summarizes the 
comparison of MD and PSD from the MRF application and HFA.  
When comparing results from all patients, the MRF underestimates the MD and 
PSD compared to that of the HFA (p <0.05). The false negative rates from the MRF 
were also found to be significantly higher than HFA (p=0.03) than that of HFA. The 
mean test duration for the MRF was 3 min 52 sec ± 40 sec compared to HFA’s 5 min 43 
sec ± 1 min 12 sec for HFA (p <0.001). Despite the added time taken to play voice 
prompts and move the fixation point, the MRF test still took less time to perform than did 
the HFA. The MRF was unable to detect a blind spot in 24% of patients. Of those who 
were able to detect a blind spot, the MRF recorded high fixation loss (36.3 ± 40.5%). 
The fixation loss monitor was only used for HFA results in UNC patients and no 
significant difference was found between the MRF and HFA (26.50% ± 39.24% and 
13.76 ± 15.44% respectively). 
A subgroup analysis included comparing results from the UNC cohort and Tema 
cohort separately and revealed varying results for both groups. Results from the UNC 
cohort showed a significant underestimation of MD results registered by the MRF 
compared to the HFA (p <0.01). In contrast, the PSD was similar between the two 
devices (p= 0.81). On the other hand, MRF results in the Tema cohort did not show a 
significant difference between the MD results of the MRF and HFA (p= 0.89). The MRF 
did however register a more positive PSD result compared to the HFA (p <0.01). In both 
the UNC and Tema cohorts, the FPR and FNR for the MRF and HFA were not 
significantly different (p >0.05). Both groups also demonstrated a significant decrease in 
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the amount of time needed to perform testing with the MRF (p <0.01). 
Correlation and Agreement Between MRF and HFA 
There is an overall strong correlation between MD results from MRF and HFA 
(r=0.71. p <0.001) with a linear regression slope of 0.68 (Figure 4a). The correlation 
PSD between the two methods was significantly moderate (r=0.48, p=0.008, 
slope=0.58). Figure 4c. Bland Altman analysis demonstrated that the mean difference in 
MD between MRF and HFA was 1.8 ± 0.41 dB (95% limits of agreement (LOA): −6.9 to 
11.0) (Figure 4b). Such a difference in PSD was 1.5 ± 0.34 dB (95% LOA: −5.7 to 8.8), 
as shown in Figure 4d. In both cases, 95% of the differences were within the LOAs, 
which were too wide for a good agreement. The UNC and Tema results were not 
assessed separately for correlation and agreement due to the small sample size and 
limited statistical power.  
Patient Satisfaction 
Figure 5 shows results of the Ease of Use questionnaire. Although 87% of 
patients either strongly agreed or agreed that the MRF was simple to use, 48% felt that 
the new device was difficult to learn to use. The majority of patients strongly agreed that 
they were able to learn to use the MRF quickly (79%) and that they could remember 
how to use it (60%). Seventy-two percent of respondents would use the MRF at home if 
instructed and 80% of patients would recommend it to a friend. These results suggest 






The present study was designed to test the usability of the MRF, particularly in a 
low-income setting in Africa, and to compare its results to those of the HFA, considered 
as clinical standard for testing visual field. Given its portability, affordability and output 
quality, a tablet computer is the ideal device for use as a parameter. The iPad-based 
MRF makes use of this technology by acting as a visual field testing application on a 
tablet. Several studies have demonstrated the reliability of the MRF for detecting visual 
field deficits, measured against the HFA.8–10 In this study, we undertook an independent 
assessment of the MRF in both a high and low-resource setting. 
When comparing results from both sites, the MRF showed a statistically 
significant difference in mean MD, PSD and FNR compared to HFA. Although, the MRF 
and HFA global indices correlated strongly for MD and moderately for PSD, the 
agreement analysis indicated that MRF tended to generate lower MD but higher PSD 
values than HFA. In both agreement analysis, the mean differences were significant, 
suggesting a poor agreement between the two devices. Unfortunately, this bias means 
that signs of early glaucomatous changes may be missed by MRF screening.  
The UNC cohort demonstrated a significant difference in MD between MRF and 
HFA (p <0.01). This difference may be due to either one or several of these factors 
combined: a) patient positioning and failure to keep an adequate viewing distance 
throughout testing, b) adequate luminosity due to absence of the viewing box as 
recommended by the manufacturer8 and c) learning curve effect.  
The UNC cohort was tested without the use of a spacer device. Although patients 
were closely monitored, many were unable to maintain the appropriate distance from 
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the iPad screen. Vingrys et al. determined that a change in viewing distance from 33 cm 
to 25 cm would increase the spot area by 1.7 times, while increasing the viewing 
distance to 75 cm would shrink the spot area by a factor of 5.8 This increase in area 
associated with a 25 cm viewing distance would have no major affect on results, 
whereas the change to a 75 cm viewing distance would reduce threshold by about 6 dB. 
Data obtained from the UNC cohort were likely biased by increasing viewing distance, 
which decreased threshold and reduced the size of any detected scotoma. Additionally, 
the lack of a viewing box may lead to glare from external light sources which may affect 
the maximum dynamic range of the iPad screen. Lastly, all patients were new to the 
MRF and were only tested once with the device. Kong et al. previously found a minimal 
learning effect between test and retest.9 The majority of their patient population were, 
however, quite familiar with the HFA, and these methods may have carried over the to 
the MRF. Our population, included many patients who were new to both the HFA and 
MRF and may benefit from test-retest of visual field, indicating that the results may have 
been affected by the learning effect.  
Unlike the UNC cohort, the Tema cohort did not show a statistical difference 
between the MD registered by the MRF and HFA. This difference was likely due to the 
construction of a custom viewing box. The accessory served to act as a visual aid for 
maintaining appropriate viewing distance and to decrease light entering into the testing 
area. Future use of the MRF would likely benefit from the use of accessories which fix 
the head at an appropriate viewing distance.  
Another potential cause of the poor agreement between the two devices is the 
lack of a direct monitoring of fixation loss. The blind spot monitor was unable to detect a 
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blind spot in 24% of patients, suggesting that these patients were unable to maintain 
fixation during the initial part of testing. Without further monitoring, it is difficult to 
determine if this loss of fixation continued throughout the rest of testing. Of those who 
were able to detect a blind spot, the MRF recorded high fixation loss (36.3% ± 40.5%). 
A reliable field using automated perimetry is defined as fixation loss less than or equal 
to 20%.12 The high fixation loss reported here is likely to affect the reliability of MRF 
results. There was however, no statistical difference in fixation loss registered by the 
MRF and HFA (p=0.86) in the UNC cohort. Due to the lack of data, I was unable to 
perform the same analysis in the Tema cohort. Despite high fixation loss, the majority of 
false positive and false negative rates were less than or equal to 25%. There were no 
patients with a false positive rate greater than 25%. Additionally, no significant 
difference was found between FNR registered by the HFA and MRF (p >0.05). Twenty-
eight percent of patients had moderate to advanced glaucoma, which may cause a high 
false negative rate to occur at the edges of scotomas and must be accounted for when 
evaluating reliability. 
Despite these limitations, patients generally felt that the MRF was easy to perform 
and simple to use. Major themes arising from the Ease of Use Questionnaire included 
the reduced testing time, ability to learn quickly how to use it, and improved comfort of 
the iPad-based testing. Patients reported willingness to use the device outside of 
traditional clinical setting, suggesting the potential acceptance of the MRF as a form of 
at-home monitoring.  
Other limitations to our study include the small sample size. The small number of 
participants significantly reduced our statistical power and likelihood of determining a 
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meaningful difference between the HFA and MRF, if one exists. It is possible that with a 
larger sample or with a test and retest, the agreement between the two devices would 
have been negligible. Thus, future studies should include a larger cohort. Secondly, 
subgroup analysis should be performed to determine reliability of the MRF when 
detecting scotomas in varying visual field quadrants.  
Finally, we conducted this pilot study in a very high-resource setting and in a 
setting with low availability of resources. Prior to testing in Ghana, the Kittner Eye 
Center cohort had considerable difficulty with correctly performing the MRF—
maintaining adequate distance from the iPad screen and following overall instructions. 
This was worrisome in a high-resource setting where patients spoke primarily English 
and were experienced in performing the HFA. Anticipation of similar yet magnified 
challenges in Ghana led to procedure changes such as creating a viewing box and 
patient procedure checklist. Despite the usefulness of these accessories, these 
additions limit the MRFs use in a low resource setting. It may be difficult to construct 
and transport these add-ons in an impoverished or remote area. The language barrier 
also created issues when performing MRF testing. Although most people in Ghana 
speak English as a second language, a translator was needed to properly instruct 
patients on the procedure. Without such help, patients would have likely struggled with 
performing testing. Finally, the MRF must be played from an iPad. The relative low-cost 
of the device does make it a better option for visual field testing but it is still an expense 
that many clinics and public health agencies are unable to afford. 
Despite these limitations, the MRF shows promise as a form of screening and 
monitoring in a low resource setting. Its portability, minimal infrastructure demands, and 
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limited requisite skills and training needed to administer the testing make it a reasonable 
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Figure 1. Patient positioning with viewing box 
 
Patient positioned at 33 cm or 13 inches from the tablet screen. Viewing box side walls 
are measured to be 13 inches and act as a visual guide for patient and person 
administering test.  
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Figure 2. Melbourne Rapid Field Application 
 
Left image: Initial perimetry testing to an island of vision measuring 15° x 12° from 
central fixation (red dot in the middle). Right image: Peripheral vision (30° along the 
horizontal and 24° along the vertical) tested by moving the fixation point each of the four 
corners of the screen. 
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Figure 3. Representative Visual Field Outcomes by MRF and HVF 
 
Representative visual fields of 3 eyes with mild (figure 3a), moderate (figure 3b) and 
advanced visual field loss (figure 3c). Lower panels are Melbourne Rapid Field (MRF) 
outcomes and upper panels correspond to Humphrey Field Analyzer SITA Standard 24-
2 outcomes thresholds and total deviation plots for the same patient. MD, mean 




Figure 4. Correlation between MRF and HFA 
 
Linear regression analysis (figure 4a) and Bland-Altman plot (figure 4b) of global indices 
for MD of MRF and HFA. Linear regression analysis (figure 4c) and Bland-Altman plot 
(figure 4d) of global indices for PSD of MRF and HFA. 
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0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Liked it better than the Humphrey test
Would not recommend it to a friend
Would use it at home
Hard to use
Learned to use it quickly
Did not understand the verbal instructions
Can remember how to use it
Difficult to learn to use
Would not like to use it every day
Simple to use




Table 1. Basic Patient Demographic and Clinical Characteristics  
 





Gender p = 0.959 
Female 6 (43%) 11 (73%)  
Male 8 (57%) 4 (27%)  
Race p = 0.077 
Non-Hispanic White 5 (36%) 2 (33%)  
Non-Hispanic Black 6 (43%) 13 (87%)  
Hispanic White 1 (7%) 0 (0%)  
Hispanic Black 0 (0%) 0 (0%)  
Other 2 (14%) 0 (0%)  
  
Age, years 61 (12, 42-75) 42 (15, 18-76) p = <0.001 
Years of Education, years  14 (2, 10-18) 15 (5, 7-21) p = 0.786 
    
MD by HFA  -8.12 ± 7.30 5.40 ± 4.17 p = 0.008 
PSD by HFA -2.47 ± 2.01 2.21 ± 0.66 p = 0.007 
    
HFA Visual Field Loss, N (%)    
Mild  7 (50%) 14 (93%)  
Moderate  4 (29%) 1 (7%)  
Advanced 3 (21%) 0 (0%)  
 
MD = mean deviation; PSD = pattern standard deviation; HFA = Humphrey visual field 
analyzer; SD = standard deviation; Mild = MD no worse than -6 dB; Moderate = MD 




Table 2. Descriptive Statistics of Visual Field Parameters 
 
Testing 
Parameter Device All patients UNC Tema 
MD, dB HFA -5.20 ± 5.92 -9.36 ± 7.75 -2.65 ± 2.06 
 MRF -3.35 ± 5.74 -4.27 ± 7.41 -2.79 ± 4.60 
 p 0.04 <0.01 0.89 
PSD, dB HFA 3.75 ± 3.31 5.83 ± 4.27 2.48  ± 1.67 
 MRF 5.30 ± 3.87 5.57 ± 4.06 5.13 ± 3.85 
 p 0.03 0.80 <0.01 
FPR , % HFA 2.79 ± 3.51 1.09 ± 1.58 3.83 ± 3.97 
 MRF 2.48 ± 4.95 1.09 ± 3.62 3.33 ± 5.53 
 p 0.75 1 0.73 
FNR, % HFA 4.88 ± 6.54 5.55 ± 7.33 4.47 ± 6.20 
 MRF 13.55 ± 22.67 15.36 ± 27.36 12.44 ± 20.07 
 p 0.03 0.22 0.43 
Duration, min  HFA 5min 43sec ± 43sec 5min 51sec ± 1min 25 sec 5min 38sec ± 56sec 
 MRF 3min 52sec ± 40sec 3min 52 sec ± 1min 44sec 3min 53sec ±  39sec 
 p <0.01 <0.01 <0.01 
Fixation Loss, % HFA  13.76 ± 15.44  
 MRF 36.32 ± 40.4 26.50 ± 39.24 41.93 ± 41.52 
 p  0.86  
 
 
MD = mean deviation; PSD = pattern standard deviation; HFA = Humphrey visual field 




Table 3. Correlation and Agreement of MD and PSD from MRF and HFA  
 
   r = Pearson’s correlation coefficient, m = linear regression slope; LoA = Limits of   
















 MD PSD 
  Correlation Agreement Correlation Agreement 
Measure r (m) p Bias 95% LoA r (m) p Bias 95% LoA 
Overall 0.71 (0.68) <0.001 1.8 ± 0.41 -6.9, 11 
0.48  
(0.56) 0.008 -1.5 ± 0.34 -5.7, 8.8 
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APPENDIX 1: Systematic Review of Current Tablet-based Visual Field Testing 
INTRODUCTION 
Glaucoma is the second leading cause of visual loss worldwide (12.3%) behind 
cataracts.1 In contrast to cataract, the vision loss sustained from glaucoma is 
irreversible. Recent international initiatives to eliminate this avoidable cause of 
blindness have included the World Health Organization’s Vision 2020 campaign.2 It is 
estimated that by 2040, global prevalence of glaucoma will increase to 111.8 million, 
with a large percentage living in developing countries.3 Non-industrialized nations face a 
larger burden of disease primarily due to assess to care, poor adherence to treatment 
and lack of follow-up.4  
The most common types of visual field deficits caused by glaucoma result from 
damage to the arcuate fibers leading to peripheral vision loss. This loss can be can be 
detected through visual field testing. Perimetry refers to the regular testing of the visual 
field and is an important part of measuring progression of glaucoma. Current visual field 
testing is primarily done in the clinical setting using standard automated perimetry 
(SAP). Once diagnosed with glaucoma, further testing recommendations include 
performing six visual field examinations within the first 2 years after diagnosis.5 This 
defined frequency of testing is needed to rule out rapid visual field loss (−2 dB/year or 
worse) with an adequate statistical power. It also allows for detection of progression 
while minimizing unnecessary use of health care resources.6 However in clinical 
practice, patients typically receive two visual field tests in the first 2 years after 
diagnosis.7 On average, it takes 4 years for a patient to receive the recommended 
number of visual field tests to detect progression rate of glaucoma.8  
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Although patients are generally willing to undergo visual field testing 
recommended by a clinician, the cost of the SAP, unavailability, and lack of portability 
limits its use in impoverished and remote areas. With increasing technologic 
advancement, comes a need to develop easy-to-use options for testing visual fields 
outside of the traditional clinic setting. This article is a systematic review of current 
portable visual field testing devices and is based on previously conducted studies. This 
included addressing the following questions: 
Q1: How accurate and reliable is the novel method compared to the gold standard for 
diagnosis and monitoring of visual deficits? 




I identified potential studies by conducting a systematic search using PubMed, 
Cochran Library, EMBASE and Global Health for articles of any design and published in 
a peer-reviewed journal during any timeframe. A similar search was used in 
clinicaltrials.gov to determine ongoing studies. The search strategies employed heading 
and keywords including "remote” and “monitoring" and "glaucoma", “remote” and 
“patient monitoring” and “glaucoma”, “home” and “monitoring” and “glaucoma”, 
“telemedicine” and “glaucoma”, “teleophthalmology” and “glaucoma”, “ophthalmic” and 
“telemedicine” and “glaucoma”, “digital monitoring” and “glaucoma”, and “teleglaucoma”, 
excluding case reports, comments, letters, editorials, and review articles. Potential 
studies were also extracted from searching through references of articles identified 
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through the initial systematic search.  
Study Selection 
Studies of any design were included which involved healthy adults (18 years or 
older) or adults with glaucoma after 1999 (Table 1. PICOTSS). Studies were eligible for 
inclusion if they considered novel methods for testing visual fields in both traditional 
clinical settings as well as non-traditional (outside of clinic) settings. Outcomes of 
interest included reliability/validity results, progression of visual field impairment (patient 
reported outcomes and visual field loss), changes in medical regimen based on home 
results, progression of optic nerve damage and possible harms associated with use of 
these novel devices. Studies published prior to 1999 were excluded because of the 
nature of the systematic review. Advancements in technology within the field of 
ophthalmology have increased substantially since the early 2000s and technology 
developed prior to this time is likely to be outdated. Studies with children and 
adolescents with glaucoma were excluded given the differing management compared to 
adult patients. Adults with intellectual disabilities were also excluded due to the likely 
difficulty that these patients may have with self-administering tests of this nature.  
Data extraction and quality assessment 
One reviewer screened titles and abstracts for full text review. Data extracted 
from articles included study characteristics such as intervention studied, parameter 
tested and outcomes of interest (benefits and harms of using the device). The same 
reviewer assessed methodological quality of each study based on the QUADAS-2 tool. 




Selection of Studies 
562 studies were screened for inclusion, 214 of which were excluded as 
duplicates and 259 were removed after reading titles and abstracts (Appendix figure 1). 
Following full-text review of 88 studies, 5 journal articles met inclusion criteria 
(Appendix, Table 1). Of 84 studies excluded, the majority of studies were removed 
because of incorrect intervention studied (29), a lack of availability of a free full text 
version online (15), and wrong study design (10). 
Tablet-based Visual Field Applications 
Several tablet-based applications for visual field testing have been developed in 
the last several years. The Visual Fields Easy and Melbourne Rapid Field applications 
facilitate perimetry by requiring the patient to signal (by entering a key on the iPad 
keyboard or pressing the iPad screen directly) whenever they see a light in their field of 
vision. The data is first accessed for reliability, i.e. did the patient lose concentration, 
close their eyes or press the buzzer too frequently. Once reliability is adequately 
determined, total mean deviation and pattern standard deviation from the age-corrected 
norm is calculated.10,11  
The Melbourne Rapid Field (MRF) application was developed in 2016 for testing 
visual field on an iPad.12 The MRF uses either a modified 24-2 grid or radial orientation 
centered at fixation. To determine central and peripheral visual defects, a total of 66 
points are tested. This is in contrast to the Humphrey 24-2 SITA Standard which tests 
only 54 points. Testing begins with fixation at the center of the iPad, limiting testing to 
an island of vision measuring 15° x 12° from central fixation. To test the periphery (30° 
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along the horizontal and 24° along the vertical), the fixation point is moved to the four 
corners of the iPad screen. Recent studies have shown a strong correlation between he 
MRF and the Humphrey Field Analyzer (HFA) as well as good intrasession test-retest 
repeatability.12,13  
In two recently published prospective studies, perimetric results for glaucomatous 
and non-glaucomatous patients were compared between the MRF application and the 
HFA.11,13 Although there was a tendency for the MRF to give less negative mean 
deviation values (1.4 dB bias) compared to the HFA, results still showed a strong 
correlation between the two results (mean deviation intraclass correlation coefficient: 
0.93, pattern deviation intraclass correlation coefficient: 0.86).10 When stratifying for mild 
HFA defects, the correlation between the two tests decreased but still remained within 
an acceptable range (mean deviation intraclass correlation: 0.77, pattern deviation 
intraclass correlation: 0.53).10 The MRF also correlated strongly with HFA across 
multiple within a 6-month period.14 
Limitations to the tablet-based visual field include lack of direct measurement of 
patient gaze stability. Fixation loss is estimated only when testing with central fixation by 
using a blind-spot monitor. The blind spot is first located at the beginning of the 
examination and the patient is later presented with a stimulus at this spot. Fixation loss 
is detected when the patient notes this stimulus during testing. Unfortunately, the blind 
spot monitor cannot be utilized when the fixation point moves to the four corners of the 
screen and instead verbal instructions direct the subject to fixate on this new point 
throughout testing. Another issue that arises during testing is the lack of procedure for 
monitoring alignment (eye and head position). Fixation losses were higher with the MRF 
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application (36% ± 4%) compared to the HFA (6% ± 1%).10 
A similar application, the Visual Field Easy (VFE) underwent testing in Nepal.15 It 
uses the same concept of a central fixation point which moves to the four corners of the 
screen to test peripheral vision loss. In 210 non-glaucomatous patients and 183 
glaucomatous patients, the VFE showed strong correlation compared to the HFA (mean 
deviation rs=0.79, pattern standard deviation rs=0.60). The VFE was able to detect most 
moderate and advanced visual field deficits (MD of -6 to -12 dB and worse than -12 db). 
There was however, an elevated false positive rate due to the difficulty in detecting early 
visual field loss (MD better than -6 db).15 
Results of the VFE and MRF applications are limited by the lack of a tracking 
system for monitoring head and eye positions.11,15,16 Although not directly monitored, 
fixation loss is minimized by regular voice prompting played by the application. 
Additionally, all studies were performed in a regular clinic setting with supervision by 
trained technicians. It is difficult to determine whether similar results would be obtained 
in a less controlled home environment.  
The PERCEPT visual performance test is a new tablet-based test which uses an 
increasingly difficult visual task to detect central visual field loss.17 It does so by first 
simultaneously presenting a “tumbling E” as the central task and a vertically oriented 
achromatic Gabor patch at 7.7 degrees from central fixation as the peripheral target. 
The patient is asked to identify the orientation of the “E”. They then must simultaneously 
determine the direction of the tumbling E and location of the peripheral target by 
touching the tablet screen. The test progresses with decreasing presentation times—
beginning at 1000 ms and gradually decreasing to 16.67 ms. Two successive correct 
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answers are needed to progress to a more difficult testing level. The test ends when the 
PERCEPT registers three consecutive incorrect answers. The shortest presentation 
time (PERCEPT processing speed in milliseconds) in which the patient can correctly 
answer is recorded. 
In a recent study including 71 glaucoma patients and 49 control patients, the 
PERCEPT had a significantly lower processing speed for patients with glaucoma 
compared to controls (difference: 243 ms; P<0.001).17 Age-adjusted ROC curve areas 
were used to understand if varying PERCEPT processing speeds could be used to 
discriminate glaucoma from control patients as determined by Standard Automated 
Perimetry (SAP) 24-2 binocular MS. The PERCEPT processing time showed 
considerable increases in discrimination with increasing severity of glaucoma. At 
random SAP 24-2 binocular MS values of 26dB, 23dB, and 20dB, the sensitivities for 
detecting glaucomatous patients at these severities were 39%, 72% and 92%. The 
PERCEPT processing speed was significantly associated with results from SAP 24-2 
binocular MS (R2 = 41%) and SAP 10–2 binocular MS (R2 = 30%). These findings 
suggest that although there is a significant correlation between SAP and PERCEPT 
results, the PERCEPT can only significantly discriminate glaucoma and control subjects 
in very severe disease. Thus, the use of PERCEPT is limited. The ideal testing device 
would detect glaucoma at an earlier stage so treatment can begin prior to significant 






The use of technology-enabled care is a promising patient management approach 
to monitoring and treating chronic conditions. With the increasing number of chronically 
ill patients and decreasing number of medical providers, comes a great need for health 
information technology. Implementing such technologies will require further research on 
acceptability of these devices and feasibility in both developed and developing 
countries.  
The three applications currently available for Visual Field testing on a tablet 
include the Melbourne Rapid Field (MRF), Visual Field Easy (VFE), and PERformance 
CEntered Portable Test (PERCEPT).  The MRF and VFE show promise for screening of 
glaucoma as well as at-home monitoring. The MRF testing shows strong correlation to 
the HFA. The results however, tend to underestimate the true severity of glaucomatous 
changes. The MRF may still be a good tool for screening despite the likelihood of 
missing early cases of glaucoma. Unfortunately, this creates an issue when it is most 
important to detect the changes early so as to avoid any further vision loss. The MRF 
has only been studied in developed nations and generalizability cannot be extended to 
low-resource areas. On the other hand, VFE has been tested in Nepal where it shows 
moderate correlation to HFA. Improvements to both devices should include a direct 
fixation loss monitor that utilized the tablets own camera. Patient positioning should be 
monitored closely and the use of an accessory to ensure appropriate visual distance 
from the tablet screen should be applied. 
Unlike the MRF and VFE, the PERCEPT is likely not an ideal method for 
screening of glaucoma. The PERCEPT processing time (shortest presentation time that 
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the patient can correctly record an answer) does not adequately discriminate early 
cases of glaucoma. The test is only able to significantly discriminate between glaucoma 
and control cases in advanced disease. The ideal screening method is one in which 
disease is detected early to allow for early treatment. Although the PERCEPT would 
likely identify severe cases of glaucoma, it would also miss many mild and moderate 
cases. 
All testing has included patients within the regular clinic setting and assisted by a 
technician. It is likely that these results would be much different in the hands of an 
untrained or under-trained patient. Further studies should include testing the MRF, VFE, 
and PERCEPT without direct supervision and in the home setting. This would help to 
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Table 1. PICOTSS Table 
 Inclusion Criteria Exclusion Criteria 
Population(s) Adults ages 18 years or older with and without glaucoma 
• Children and adolescents 
• Adults with intellectual 
disabilities 
Interventions iPad-based visual field (VF) testing   
Comparators 
Correlation between iPad-based 
VF testing and gold standard, 




Primary: Level of agreement 
between the iPad-based VF 
testing and HFA 
 
Secondary: 
Progression of visual field 
impairment (patient reported 
outcomes and visual field loss) 
 
Changes in medical regimen 
based on home results, 
progression of optic nerve 
damage, harms 
 
Timing Studies published after 1999  
Settings 
Self-administered testing 
performed in traditional (clinic) 
and non-traditional settings 
(outside of the clinic), any country 
 
Study Designs 
Randomized control trials, cohort, 
case-control, cross-sectional 
studies 
Case reports, comments, 






Table 2a. Systematic Review Articles 
First Author, 
Year, Country 
Kong, Australia, 20168 Schulz, Australia, 20179 
Research Design Non-randomized Clinical Trial Non-randomized Clinical Trial 
Intervention Melbourne Rapid Visual Field (MRF) 
iPad Application 
Melbourne Rapid Visual Field (MRF) 
iPad Application 
Measurement Visual Field Visual Field 
Comparators MRF(c) vs Humphrey Visual 
Analyzer(c) 
MRF(c) vs Humphrey Visual Analyzer(c) 
Setting MRF(c) and HFA(c): Clinic MRF(c) and HFA(c): Clinic 
Source Population Recruited from the Glaucoma 
Investigation and Research Unit of 





90 subjects (age: 18–91, mean: 69.5, 
standard deviation [SD]: 12.5)—78 had 
glaucoma and 12 had healthy optic 
nerves and normal visual field tests on 
HFA. 
145 subjects (60 open angle glaucoma 
patients including 43 with manifest field 
defects and 17 pre-perimetric subjects 
and 25 controls 
Inclusion Criteria 1)Visual acuity of 6/12 (20/40) or better 
and 2) gave reliable HFA-SITA 
Standard 24-2 test outcomes within 3 
months of MRF testing (false-positive 
less than or equal to 15% and 
fixation losses and negative responses 
less than or 
equal to 20%). 
1)Intraocular pressures within their 
target range and 2) stable HVF. 
Exclusion Criteria Retinal or corneal disease, required an 
English interpreter (as they would not 
be able to follow iPad instructions) or 
had intraocular surgery within 6 months 
of the study. 
Did not report 
Follow-Up Time 90% of patients had HFA on the same 
day as MRF, the others had HFA 
performed no more than 3 months prior 




MRF(c) vs HFA(c):  
- Overall: 
o Mean deviation 
§ ICC: 0.93 (95% CI 
0.90, 0.95) 
§ r= 0.9 
o Pattern deviation  
§ ICC: 0.86 (95% CI 
0.84, 0.93) 
§ r=0.7 
MRF(c) vs HFA(c): 
- Overall: 
o Mean deviation 
§ r2= 0.80 (P < 
0.0001) 
§ ICC: 0.95  
§ rs= 0.80 (P < 
0.0001) 
o Pattern deviation  







o HFA returns slightly more 
negative MD values 
compared with the MRF 
for participants with 
greater field loss (Bland-
Altman slope of 0.09). 
- Mild  
o Mean deviation 
§ ICC: 0.73 (95% CI 
0.57, 0.83) 
§ r=0.6 
o Pattern deviation  
§ ICC: 0.74 (95% CI 
0.59, 0.84) 
§ r=0.7 
- Moderate to Severe: 
o Mean deviation 
§ ICC: 0.91 (95% CI 
0.84, 0.96) 
§ r=0.8 
o Pattern deviation  




§ ICC: 0.94  
§ rs= 0.85 (P < 
0.0001) 
o Visual Field Index vs VC 
§ r2= 0.85 (P < 
0.0001) 
§ ICC: 0.95 






Did not report Did not report  
Harms Did not report Did not report  
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Table 2b. Systematic Review Articles Continued 
First Author, 
Year, Country 
Johnson, Nepal, 201721 Prea, Australia, 201824 
Research Design Non-randomized Clinical Trial Non-randomized Clinical Trial 
Intervention Visual Fields Easy (VFE) iPad 
Application 
Melbourne Rapid Visual Field (MRF) 
iPad Application 
Measurement Visual Field Visual Field 
Comparators VFE(c) vs Humphrey Visual Analyzer 
24-2 SITA Standard program(c) 
MRF(c) vs Humphrey Visual Analyzer(c) 
Setting VFE(c) and HFA(c): Clinic MRF(c) and HFA(c): Clinic 
Source Population Subjects living near Kathmandu, 
Nepal, who attended the Tilganga 
Institute of Ophthalmology, 





206 subjects (105 normal, 92 
glaucoma, 9 diabetic retinopathy) 
60 subjects (Cambridge n = 39, age: 37-
89 years; mean: 70.1 years; Dehli n= 21; 
age: 15-59 years; mean: 35.3 years) 
Inclusion Criteria 1) Were able to provide a correct 
assessment of age 
Stable ocular hypertension (IOP > 21 
mm Hg with normal visual field [VF] and 
optic nerve), had stable treated 
glaucoma (optic nerve and/or VF 
changes consistent with glaucoma and 
diagnosis confirmed by fellowship-
trained glaucoma subspecialists), 
or were glaucoma suspects (IOP < 21, 
with subtle changes in optic nerve 
and/or VF that do not 
meet definitive diagnosis of glaucoma). 
Exclusion Criteria 1) Best corrected visual acuity of 20/60 
or worse, 2) Uncorrected refractive 
error of greater than 4 diopters sphere 
and/or 3 diopters cylinder, 3) had other 
ocular, neurologic, or systemic 
conditions that may affect visual field 
sensitivity or 4) were taking 
medications that were known to affect 
visual field sensitivity.  
Presence of a systemic condition or use 
of systemic drugs that could affect 
vision, a need to change glaucoma 
medications or undergo eye surgery 
over the review period or in the 
preceding 6 months, inability to 
understand or comply with the English 
voice commands of the MRF, visual 
acuity worse than 6/12 (20/40), and poor 
reliability indices on HFA at baseline 
(fixation loss > 30%, false positive 
>15%, false negative >20%). 
Follow-Up Time Same Day 2, 4 and 6 months from baseline. 
Validity and 
Reliability 
VFE(c) vs HFA(c): 
- Overall: 
o Mean deviation 
§ rs= 0.79 (P < 
0.0001) 
o Pattern deviation  
§ rs= 0.60 (P < 
MRF(c) vs HFA(c):  
- Overall: 
o Mean time to complete: 4.6 
± 0.1 mins 
o MD SITA-Fast vs MD MRF 
- Baseline:  
o Ca: 0.67 
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0.0001) 
o Number of locations that 
were worse than the 95% 
confidence limits for total 
deviation 
§ r= 0.51 (P < 
0.0001) 
o Pattern deviation 
§ r= 0.68 (P < 
0.0001) 
o ICC: 0.71 (95% CI 0.353, 
0.83) 
o Bias: -2.9 
o 95% LoA, dB: -5.5, -0.5 
- 2 months:  
o Ca: 0.78 
o ICC: 0.82 (95% CI 0.68, 
0.89)  
o Bias: -3.4 
o 95% LoA, dB: -4.6, -2.2 
- 4 months:  
o Ca: 0.81 
o ICC: 0.88 (95% CI 0.78, 
0.92)  
o Bias: -3.1 
o 95% LoA, dB: -4.7, -1.5 
o 6 months:  
§ Ca: 0.82 
§ ICC: 0.87 (95% CI 
0.77, 0.92)  
§ Bias: -2.9 
§ 95% LoA, dB: -4.5, -
1.3 
 
- MD SITA-Standard vs MD MRF 
- Baseline:  
o Ca: 0.79 
o ICC: 0.81 (95% CI 0.67, 
0.89) 
o Bias: -2.2 
o 95% LoA, dB: -3.2, -1.3 
- 2 months:  
o Ca: 0.85 
o ICC: 0.88 (95% CI 0.78, 
0.93)  
o Bias: -1.3 
o 95% LoA, dB: -2.1, -0.4 
- 4 months:  
o Ca: 0.86 
o ICC: 0.90 (95% CI 0.82, 
0.94)  
o Bias: -1.2 
o 95% LoA, dB: -2.0, -0.4 
- 6 months:  
o Ca: 0.83 





o Bias: -1.9 




Did not report  Did not report 
Did not report 




Table 2c. Systematic Review Articles Continued 
First Author, Year, 
Country 
Rosen, United States, 201526 
Research Design Non-randomized Clinical Trial 
Intervention PERformance CEntered Portable Test (PERCEPT) 
Measurement Visual Field 
Comparators PERCEPT(c) vs Humphrey Visual Analyzer 24-2 SITA Standard 
program(c) 
Setting PERCEPT(c) and HFA(c): Clinic 





130 subjects (59 normal and 71 glaucoma):  Ages 70 ± 12 years 
and 61 ± 13 years, respectively (P<0.001) 
Inclusion Criteria Did not define 
Exclusion Criteria Did not define 
Follow-Up Time Same Day 
Validity and 
Reliability 
-  Significantly lower processing speed for patients with 
glaucoma compared to controls (difference: 243 ms; 
P<0.001). 
-  At arbitrary values SAP 24-2 binocular MS values of 26dB, 
23dB, and 20dB, the sensitivities for discriminating between 
glaucoma and control patients at these severities were 
39%, 72% and 92%. 
- The PERCEPT processing speed was significantly 
associated SAP 24-2 binocular MS results (R2 = 41%) and 
SAP 10–2 binocular MS (R2 = 30%). 
Patient Reported 
Outcomes 
Did not report  
Harms Did not report 
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Study Title: Glaucoma Screening Using an iPad-based Visual Field Test: A 
Feasibility Study, IRB # 18-0054 
Thank you very much for participating in this short research survey! I am 
studying a new way of measuring your visual field.  Your answers to this survey 
will help us learn whether this new way is as good or better than what your doctor 
has been using with you.  
I will also be using information about your eyes from your chart to help study the 
use of this new visual field testing. If you agree to participate, I will add this 
survey information to what is found in your chart. Your medical record number 
will be obtained in connection with this study and any identifying information will 
remain confidential. You will not be identified in any of the information we get 
from this study and your medical record information will be destroyed after 
finishing the study. 
 
This study has been approved by the Institutional Review Board (IRB) at the 
University of North Carolina. You can stop it at any time or skip any questions 
that make you feel uncomfortable.  
 
If you have questions, you can reach the UNC IRB at 919-966-3113 and you can 
call my faculty advisor, Dr. Sue Tolleson-Rinehart, at 919-843-9477.  
 
Do you agree to allow me to review information about your eyes in your medical chart?   
 
Please circle one:       YES  NO 
 
Are you willing to answer questions in this survey?   
 
Please circle one:        YES   NO  
 
Thank you!  If you are willing to answer questions, please turn to the next page. 
 
In general, how would you rate your health right now?  
a. Excellent 






Compared to one year ago, how would you rate your general health today? 
a. Much better now than one year ago 
b. Somewhat better now than one year ago 
c. About the same 
d. Somewhat worse now than one year ago 
e. Much worse now than one year ago 
 
Would you mind telling us how many years of school you have? __________________ 
 
Do you own a cellular phone? Circle one:       YES       NO 
 
Is your cellular/mobile phone an Iphone, Android, or a Blackberry?  
Circle one:         YES      NO 
 
If not one of the above, what type of cellular/mobile phone do you use?  
________________________________ 
 
Do you use an Ipad or any other tablet on a regular basis?    
Circle one:          YES       NO 
 
If you have a tablet, is it an Ipad or something else? 
Circle one:          Ipad  Something else 
 
Now we have some questions about the visual field test you just had.  It is called 
the Melbourne Rapid Fields Test.  For each question, please choose the answer 
that is closest to your experience with the Melbourne Test. 
 
After taking the 




Agree Neutral Disagree Strongly 
Disagree 
It is simple to use.      
I learned to use it 
quickly. 
     
I did not understand 
the verbal instructions. 
     
I can remember how to 
use it. 
     
It is hard to use.      
It is difficult to learn to 
use. 
     
I would not like to use 
it everyday. 
     
I would not 
recommend it to a 
friend. 
     
I would use it at home.      
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After taking the 




Agree Neutral Disagree Strongly 
Disagree 
I liked it better than the 
Humphrey test. 
     
 

























Thank you for your time and answers!  We greatly appreciate them!  Is there 
anything else you’d like to tell me?  You can write it below! 
 
 
